

# CITATION REPORT

List of articles citing

Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations

DOI: 10.2165/00003088-200544020-00006  
Clinical Pharmacokinetics, 2005, 44, 211-20.

**Source:** <https://exaly.com/paper-pdf/39421267/citation-report.pdf>

**Version:** 2024-04-24

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
174	Posaconazole: a broad-spectrum triazole antifungal. <b>2005</b> , 5, 775-85		226
173	Posaconazole. <b>2005</b> , 65, 1553-67; discussion 1568-9		130
172	Posaconazole: clinical pharmacology and potential for management of fungal infections. <b>2005</b> , 3, 467-87		85
171	Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. <b>2006</b> , 15, 579-602		64
170	HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. <b>2006</b> , 49 Suppl 1, 17-22		30
169	Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. <i>Clinical Infectious Diseases</i> , <b>2006</b> , 42, e61-5	11.6	490
168	Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 1993-9	5.9	124
167	Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 917-21	5.9	240
166	Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2006</b> , 50, 658-66	5.9	241
165	Effects of age, gender, and race/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 495-502	5.9	76
164	Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. <i>Clinical Infectious Diseases</i> , <b>2007</b> , 45, 1610-7	11.6	173
163	Posaconazole: a next-generation triazole antifungal. <b>2007</b> , 2, 231-43		34
162	Posaconazole plasma concentrations in juvenile patients with invasive fungal infection. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2007</b> , 51, 812-8	5.9	140
161	Posaconazole Oral Suspension. <b>2007</b> , 42, 57-72		
160	Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance. <b>2007</b> , 35, S1-23; quiz S24-6		30
159	Antimicrobial resistance prevention initiative--an update: proceedings of an expert panel on resistance. <b>2007</b> , 120, S4-25; quiz S26-8		33
158	[The latest data on posaconazole]. <b>2007</b> , 37, 71-6		6

157	Clinical pharmacology of antifungal agents in pediatric patients. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 2465-89	4	18
156	Posaconazole: a new broad-spectrum antifungal agent. <i>Expert Opinion on Pharmacotherapy</i> , <b>2007</b> , 8, 1167-78	4	34
155	Posaconazole (Noxafil): a new triazole antifungal agent. <b>2007</b> , 20, 188-96		34
154	A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma. <b>2007</b> , 43, 228-36		68
153	Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. <i>Pharmacotherapy</i> , <b>2007</b> , 27, 1627-36	5.8	144
152	[Pharmacology of azoles]. <i>Revista Iberoamericana De Micologia</i> , <b>2007</b> , 24, 223-7	1.6	7
151	Pharmacokinetic considerations for the use of newer antifungal agents. <i>Current Fungal Infection Reports</i> , <b>2008</b> , 2, 5-11	1.4	
150	Antifungal agents--clinical pharmacokinetics and drug interactions. <b>2008</b> , 51 Suppl 1, 7-18		54
149	Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. <i>Pharmacotherapy</i> , <b>2008</b> , 28, 1223-32	5.8	76
148	Current options in antifungal pharmacotherapy. <i>Pharmacotherapy</i> , <b>2008</b> , 28, 614-45	5.8	60
147	Posaconazole: an oral triazole with an extended spectrum of activity. <b>2008</b> , 42, 1429-38		39
146	[In vitro susceptibility of isolates of <i>Scytalidium</i> spp. from superficial lesions against posaconazole]. <b>2008</b> , 56, 268-71		8
145	New and investigational triazole agents for the treatment of invasive fungal infections. <b>2008</b> , 20, 661-71		21
144	Progressive fusariosis: unpredictable posaconazole bioavailability, and feasibility of recombinant interferon-gamma plus granulocyte macrophage-colony stimulating factor for refractory disseminated infection. <b>2008</b> , 49, 163-5		29
143	Posaconazole as salvage therapy in patients with invasive fungal infections after solid organ transplant. <b>2008</b> , 86, 791-6		62
142	Posaconazole in the management of refractory invasive fungal infections. <i>Therapeutics and Clinical Risk Management</i> , <b>2008</b> , 4, 747-58	2.9	19
141	Posaconazole: A new agent for the prevention and management of severe, refractory or invasive fungal infections. <b>2008</b> , 19, 297-305		12
140	Prophylaxis of Invasive Fungal Infections: A Review of the Use of Posaconazole. <b>2009</b> , 1, CMT.S1948		

139	What should be the first-choice strategy to maximize posaconazole exposure in daily clinical practice?. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 3608-9; author reply 609-10	5.9	6
138	Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 703-7	5.9	66
137	Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 5224-9	5.9	91
136	Posaconazole: a new oral antifungal agent with an expanded spectrum of activity. <b>2009</b> , 66, 225-36		25
135	Antifungal drugs: predicting clinical efficacy with pharmacodynamics. <i>Expert Review of Clinical Pharmacology</i> , <b>2009</b> , 2, 373-9	3.8	3
134	Antifungal therapeutic drug monitoring: established and emerging indications. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 24-34	5.9	386
133	Pharmacokinetics of posaconazole administered orally or by nasogastric tube in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 2960-4	5.9	32
132	Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2009</b> , 53, 958-66	5.9	282
131	Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. <b>2009</b> , 168, 313-27		29
130	What is the role of therapeutic drug monitoring in antifungal therapy?. <b>2009</b> , 11, 439-46		3
129	Tolerability and safety profile of posaconazole: evaluation of 18 controlled studies in healthy volunteers. <b>2009</b> , 34, 301-11		40
128	Antifungal therapy. <b>2009</b> , 161-195		11
127	Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. <b>2009</b> , 7, 165-81		14
126	Use of posaconazole in the treatment of invasive fungal infections. <b>2009</b> , 2, 619-30		8
125	Effects of oral posaconazole on the pharmacokinetics of sirolimus. <b>2009</b> , 25, 701-7		42
124	Overview of antifungal agents. <b>2009</b> , 30, 203-15, v		88
123	Antifungal Therapeutic Drug Monitoring. <i>Current Fungal Infection Reports</i> , <b>2010</b> , 4, 158-167	1.4	20
122	Clinical pharmacodynamics and pharmacokinetics of the antifungal extended-spectrum triazole posaconazole: an overview. <b>2010</b> , 70, 471-80		53

121	Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. <b>2010</b> , 88, 115-9		180
120	Clinically relevant drug interactions of current antifungal agents. <b>2010</b> , 53, 95-113		52
119	Clinical safety and tolerability issues in use of triazole derivatives in management of fungal infections. <b>2010</b> , 2, 27-38		10
118	Therapeutic drug monitoring of posaconazole in hematology patients: experience with a new high-performance liquid chromatography-based method. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 4029-32	5.9	25
117	Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 3609-13	5.9	29
116	Efficacy of posaconazole in a murine disseminated infection by <i>Candida tropicalis</i> . <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 530-2	5.9	7
115	Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 207-12	5.9	58
114	Population pharmacokinetics of posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. <b>2010</b> , 26, 397-405		26
113	Ultra-performance liquid chromatography mass spectrometry and sensitive bioassay methods for quantification of posaconazole plasma concentrations after oral dosing. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2010</b> , 54, 5074-81	5.9	17
112	Pharmacokinetic/pharmacodynamic profile of posaconazole. <i>Clinical Pharmacokinetics</i> , <b>2010</b> , 49, 379-96	6.2	102
111	Antifungals to treat <i>Candida albicans</i> . <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2037-48	4	50
110	Posaconazole for the treatment of mucormycosis. <i>International Journal of Antimicrobial Agents</i> , <b>2011</b> , 38, 465-73	14.3	15
109	Effect of pH and comedication on gastrointestinal absorption of posaconazole: monitoring of intraluminal and plasma drug concentrations. <i>Clinical Pharmacokinetics</i> , <b>2011</b> , 50, 725-34	6.2	98
108	Triazole antifungal agents in invasive fungal infections: a comparative review. <b>2011</b> , 71, 2405-19		173
107	Current concepts in antifungal pharmacology. <b>2011</b> , 86, 805-17		248
106	Overview of treatment options for invasive fungal infections. <i>Medical Mycology</i> , <b>2011</b> , 49, 561-80	3.9	36
105	Pharmacokinetic/pharmacodynamic optimization of triazole antifungal therapy. <b>2011</b> , 24, S14-S29		9
104	Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature. <b>2011</b> , 16, 139-44		49

103	[Level of evidence for therapeutic drug monitoring of posaconazole]. <b>2011</b> , 66, 115-22		3
102	Posaconazole: clinical pharmacokinetics and drug interactions. <b>2011</b> , 54 Suppl 1, 32-8		19
101	Optimising absorption of posaconazole. <b>2011</b> , 54, e775-9		14
100	Posaconazole: when and how? The clinician's view. <b>2012</b> , 55, 110-22		22
99	Antifungal Pharmacokinetics and Dosing Considerations in Burn Patients. <i>Current Fungal Infection Reports</i> , <b>2011</b> , 5, 67-74	1.4	
98	Update on Antifungal Drug Dosing and Therapeutic Drug Monitoring. <i>Current Fungal Infection Reports</i> , <b>2011</b> , 5, 92-102	1.4	3
97	Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients. <b>2012</b> , 46, e22		10
96	Therapeutic drug monitoring of antifungal agents <sup>1</sup> ). <b>2012</b> , 36, 1-10		
95	Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. <b>2012</b> , 19, 51-63		7
94	Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or myelodysplastic syndrome. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 6298-303	5.9	28
93	Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring. <i>Therapeutic Drug Monitoring</i> , <b>2012</b> , 34, 320-5	3.2	12
92	Making sense of posaconazole therapeutic drug monitoring: a practical approach. <b>2012</b> , 25, 605-11		27
91	Posaconazole exposure-response relationship: evaluating the utility of therapeutic drug monitoring. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 2806-13	5.9	120
90	Therapeutisches Drug Monitoring von Antimykotika/Therapeutic drug monitoring of antifungal agents. <b>2012</b> , 36,		
89	Therapeutic drug monitoring of posaconazole in allogeneic hematopoietic stem cell transplantation patients who develop gastrointestinal graft-versus-host disease. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2012</b> , 56, 5247-52	5.9	31
88	Advances in systemic antifungal therapy. <b>2012</b> , 30, 657-61		8
87	Usos actual de los antifúngicos triazoles en niños. <b>2012</b> , 16, 82-93		
86	Invasive mycoses: strategies for effective management. <b>2012</b> , 125, S25-38		62

85	Therapeutic drug monitoring of posaconazole in hematology adults under posaconazole prophylaxis: influence of food intake. <b>2012</b> , 31, 161-7		38
84	Antifungal therapy: current concepts and evidence-based management. <b>2013</b> , 29, 289-290		0
83	Posaconazole pharmacokinetics in a 2-year-old boy with rhino-cerebral-orbital zygomycosis. <i>Pharmacotherapy</i> , <b>2013</b> , 33, e1-8	5.8	8
82	Optimizing antifungal choice and administration. <b>2013</b> , 29 Suppl 4, 13-8		71
81	New antifungal antibiotics. <b>2013</b> , 26, 168-74		26
80	Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2013</b> , 57, 6081-4	5.9	21
79	Posaconazole: A Review of Drug Interactions with HIV Antiretroviral Agents. <i>Pharmacy (Basel, Switzerland)</i> , <b>2014</b> , 2, 98-113	2	1
78	Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6767-72	5.9	37
77	Optimizing azole antifungal therapy in the prophylaxis and treatment of fungal infections. <b>2014</b> , 27, 493-500		21
76	Understanding variability in posaconazole exposure using an integrated population pharmacokinetic analysis. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2014</b> , 58, 6879-85	5.9	55
75	Pharmacokinetics and pharmacodynamics of antifungals in children and their clinical implications. <i>Clinical Pharmacokinetics</i> , <b>2014</b> , 53, 429-54	6.2	29
74	Candidiasis. <b>2014</b> , 408-411.e1		
73	[Pharmacology of the antifungals used in the treatment of aspergillosis]. <i>Revista Iberoamericana De Micologia</i> , <b>2014</b> , 31, 255-61	1.6	3
72	Update on Posaconazole Pharmacokinetics: Comparison of Old and New Formulations. <i>Current Fungal Infection Reports</i> , <b>2014</b> , 8, 139-145	1.4	13
71	Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. <i>International Journal of Antimicrobial Agents</i> , <b>2014</b> , 44, 140-4	14.3	19
70	Mechanisms of Action of Antifungal Agents. <b>2015</b> , 183-196		
69	Discovering of Tumor-targeting Peptides using Bi-functional Microarray. <i>Advanced Healthcare Materials</i> , <b>2015</b> , 4, 2802-8	10.1	8
68	Agents of Mucormycosis and Entomophthoramyosis. <b>2015</b> , 2909-2919.e3		8

67	Drugs Active against Fungi, Pneumocystis, and Microsporidia. <b>2015</b> , 479-494.e4		7
66	Posaconazole: An Update of Its Clinical Use. <i>Pharmacy (Basel, Switzerland)</i> , <b>2015</b> , 3, 210-268	2	10
65	Antifungal Agents. <b>2015</b> , 79-97		1
64	Pharmacologic and clinical evaluation of posaconazole. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 321-34	3.8	34
63	Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. <i>Pharmacotherapy</i> , <b>2015</b> , 35, 208-19	5.8	42
62	Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia. <i>Journal of Infection and Chemotherapy</i> , <b>2015</b> , 21, 663-7	2.2	2
61	Antifungal Drug Therapeutic Monitoring: What are the Issues?. <i>Current Clinical Microbiology Reports</i> , <b>2015</b> , 2, 55-66	3.1	9
60	Determination of posaconazole concentration with LC-MS/MS in adult patients with hematologic malignancy. <i>Clinica Chimica Acta</i> , <b>2015</b> , 450, 220-6	6.2	12
59	Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model. <i>PLoS Neglected Tropical Diseases</i> , <b>2016</b> , 10, e0005125	4.8	17
58	Differences in Food Effects for 2 Weak Bases With Similar BCS Drug-Related Properties: What Is Happening in the Intestinal Lumen?. <i>Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 105, 2712-2722	3.9	32
57	Supersaturation and Precipitation of Posaconazole Upon Entry in the Upper Small Intestine in Humans. <i>Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 105, 2677-2684	3.9	78
56	Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients. <i>European Journal of Clinical Pharmacology</i> , <b>2016</b> , 72, 953-63	2.8	16
55	Gastrointestinal and Systemic Monitoring of Posaconazole in Humans After Fasted and Fed State Administration of a Solid Dispersion. <i>Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 105, 2904-2912	3.9	36
54	Treatment of Disseminated Aspergillosis with Posaconazole in 10 Dogs. <i>Journal of Veterinary Internal Medicine</i> , <b>2016</b> , 30, 167-73	3.1	19
53	Azole Antifungal Agents. <b>2016</b> , 77-96		
52	Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , <b>2016</b> , 62, e1-50	11.6	1655
51	Posaconazole plasma concentration in pediatric patients receiving antifungal prophylaxis after allogeneic hematopoietic stem cell transplantation. <i>Medical Mycology</i> , <b>2016</b> , 54, 128-37	3.9	16
50	Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2017</b> , 61,	5.9	24



49	Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. <i>Infection</i> , <b>2017</b> , 45, 737-779	5.8	137
48	Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2017</b> , 72, i12-i18	5.1	74
47	CYP51 as drug targets for fungi and protozoan parasites: past, present and future. <i>Parasitology</i> , <b>2018</b> , 145, 1820-1836	2.7	56
46	Antifungal Agents. <b>2018</b> , 425-501		
45	Interplay of Supersaturation and Solubilization: Lack of Correlation between Concentration-Based Supersaturation Measurements and Membrane Transport Rates in Simulated and Aspirated Human Fluids. <i>Molecular Pharmaceutics</i> , <b>2019</b> , 16, 5042-5053	5.6	22
44	Plasma exposures following posaconazole delayed-release tablets in immunocompromised children and adolescents. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2019</b> , 74, 3573-3578	5.1	9
43	Advances in pediatric antimicrobial agents development. <i>Current Opinion in Pediatrics</i> , <b>2019</b> , 31, 135-143	3.2	1
42	Using State Transition Models to Explore How the Prevalence of Subtherapeutic Posaconazole Exposures Impacts the Clinical Utility of Therapeutic Drug Monitoring for Posaconazole Tablets and Oral Suspension. <i>Antimicrobial Agents and Chemotherapy</i> , <b>2019</b> ,	5.9	8
41	Clinical Pharmacokinetics and Dose Recommendations for Posaconazole in Infants and Children. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 53-61	6.2	28
40	History of the development of antifungal azoles: A review on structures, SAR, and mechanism of action. <i>Bioorganic Chemistry</i> , <b>2020</b> , 104, 104240	5.1	37
39	Posaconazole in prophylaxis and treatment of invasive fungal infections: a pharmacokinetic, pharmacodynamic and clinical evaluation. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2020</b> , 16, 539-550	5.5	5
38	Administration and Dosing of Systemic Antifungal Agents in Pediatric Patients. <i>Paediatric Drugs</i> , <b>2020</b> , 22, 165-188	4.2	9
37	Evaluation of target attainment of oral posaconazole suspension in immunocompromised children. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2020</b> , 75, 726-729	5.1	5
36	A Population Pharmacokinetic Modeling and Simulation Study of Posaconazole Oral Suspension in Immunocompromised Pediatric Patients: A Short Communication. <i>Therapeutic Drug Monitoring</i> , <b>2021</b> , 43, 512-518	3.2	3
35	Review of Pharmacologic Considerations in the Use of Azole Antifungals in Lung Transplant Recipients. <i>Journal of Fungi (Basel, Switzerland)</i> , <b>2021</b> , 7,	5.6	4
34	Pharmacokinetics and target attainment of intravenous posaconazole in critically ill patients during extracorporeal membrane oxygenation. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2021</b> , 76, 1234-1241	5.1	3
33	Novel Antifungal Therapies. <b>2007</b> , 69-98		2
32	Azoles. <b>2011</b> , 61-93		1

31	Rational approach to pediatric antifungal therapy. <i>Advances in Experimental Medicine and Biology</i> , <b>2011</b> , 697, 231-42	3.6	2
30	Current Controversies in the Treatment of Fungal Infections. <b>2011</b> , 301-316		1
29	Antimicrobial agents, drug adverse reactions and interactions, and cancer. <i>Cancer Treatment and Research</i> , <b>2014</b> , 161, 413-62	3.5	4
28	Invasive fungal infections in children: advances and perspectives. <b>2007</b> , 405-472		1
27	Systemic Antifungal Agents. <b>2010</b> , 549-563		5
26	Agents of Mucormycosis and Entomophthoramycesis. <b>2010</b> , 3257-3269		8
25	Invasive Aspergillosis in Malignancy and Stem Cell Transplant Recipients. 519-530		4
24	Antifungals: Drug Class, Mechanisms of Action, Pharmacokinetics/Pharmacodynamics, Drug-Drug Interactions, Toxicity, and Clinical Use. 343-371		3
23	Candidiasis. <b>2007</b> , 406-408		
22	Azoles. <b>2009</b> , 230-262		
21	Newer Antifungal Agents in Pediatrics. <b>2009</b> , 414-426		
20	Pharmacology of Azole Antifungal Agents. <b>2009</b> , 199-218		
19	Posaconazole. <b>2010</b> , 1862-1870		
18	Antifungal Therapy in Patients with Hematological Malignancies. <b>2011</b> , 569-588		
17	Antifungal Agents. <b>2011</b> , 509-560		
16	Antifungal Agents *. <b>2011</b> , 1995-2007		
15	Fungal Infections. <b>2011</b> , 1050-1060		
14	15 Antifungal Pharmacokinetics. <b>2014</b> , 281-290		

13 Azoles. 417-434

12 Antifungal Agents. 2221-2235

11 Antifungal Agents. **2008**, 105-13310 Role of posaconazole in the management of oropharyngeal and esophageal candidiasis. *Therapeutics and Clinical Risk Management*, **2007**, 3, 533-42 2.9 99 Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. *Expert Opinion on Pharmacotherapy*, **2021**, 1-25 4 18 The Overview on the Pharmacokinetic and Pharmacodynamic Interactions of Triazoles. *Pharmaceutics*, **2021**, 13, 6.4 17 Azoles. **2021**, 06 Azole Therapeutic Drug Monitoring and its Use in the Management of Invasive Fungal Disease. *Current Fungal Infection Reports*, 1 1.4 05 Chemical and biological aspects of posaconazole as a classic antifungal agent with non-classical properties: highlighting a tetrahydrofuran-based drug toward generation of new drugs. *Medicinal Chemistry Research*, 2.24 Challenges in the Treatment of Invasive Aspergillosis in Immunocompromised Children. *Antimicrobial Agents and Chemotherapy*, 5.9 03 Population pharmacokinetics of posaconazole in Chinese pediatric patients with acute leukaemia: Effect of food on bioavailability and dose optimization. **2022**, 178, 106289 02 A Physiologically-Based Pharmacokinetic Model of Ruxolitinib and Posaconazole to Predict CYP3A4-Mediated Drug-Drug Interaction Frequently Observed in Graft versus Host Disease Patients. **2022**, 14, 2556 01 Integrating Forward and Reverse Translation in PBPK Modeling to Predict Food Effect on Oral Absorption of Weakly Basic Drugs. **2023**, 40, 405-418 0